- Conference Call and Webcast to Follow at 8:00 a.m. ET/ 5:00 a.m. PT
BRISBANE, Calif.--(BUSINESS WIRE)--Mar. 8, 2017--
Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company
developing treatments for life-threatening food allergies, today
announced that its financial results for the fourth quarter and full
year 2016 will be released on Wednesday, March 15, 2017, before U.S.
markets open. At 8:00 a.m. Eastern Time / 5:00 a.m. Pacific Time,
Aimmune management will host a conference call to discuss its financial
results and provide a general business update.
The conference call will be accessible via the company’s website at www.aimmune.com
on the Events page under Investor Relations. Please connect to the
company’s website at least 15 minutes prior to the start of the
conference call to ensure adequate time for any software download that
may be required to listen to the webcast. Alternatively, please call
1-877-497-1438 (U.S.) or 1-262-558-6296 (international) and provide the
conference ID # 84650109 to join by phone.
About Aimmune Therapeutics
Aimmune Therapeutics, Inc., is a clinical-stage biopharmaceutical
company developing treatments for life-threatening food allergies. The
company’s Characterized Oral Desensitization ImmunoTherapy (CODIT™)
approach is intended to achieve meaningful levels of protection by
desensitizing patients with defined, precise amounts of key allergens.
Aimmune’s first investigational biologic product using CODIT™, AR101 for
the treatment of peanut allergy, has received the FDA’s Breakthrough
Therapy Designation for the desensitization of peanut-allergic patients
4-17 years of age and is currently being evaluated in Phase 3 clinical
trials. For more information, please see www.aimmune.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170308005212/en/
Source: Aimmune Therapeutics, Inc.
Aimmune Therapeutics, Inc.
Laura Hansen, Ph.D.,